Table 1.

Discovery cohort: clinicopathological data of the Tumor Profiler Melanoma cohort used as the discovery cohort.

Clinicopathological parameters patients (n = 116)	Site of metastasis (n = 126)
	Brain (n = 15)		Soft tissue (n = 59)		LN (n = 37)		Other (n = 15)
	No.	%	No.	%	No.	%	No.	%
Gender
F	7	46.7	28	47.5	12	32.4	5	33.3
M	8	53.3	31	52.5	25	67.6	10	66.7
Age (years)
<40	2	13.3	3	5.1	2	5.4	2	13.3
40–49	3	20.0	2	3.4	2	5.4	5	33.3
50–59	6	40.0	16	27.1	13	35.1	1	6.7
60–69	1	6.7	16	27.1	8	21.6	2	13.3
70–79	2	13.3	19	32.2	8	21.6	5	33.3
≥80	1	6.7	3	5.1	4	10.8	0	0
Histological subtype
Cutaneous	12	80.0	43	72.9	31	83.8	10	66.7
Mucosal	0	0.0	3	5.1	1	2.7	3	20.0
Ocular	1	6.7	8	13.6	0	0.0	2	13.3
Unknown primary	2	13.3	5	8.5	5	13.5	0	0.0
Stage
III	0	0.0	13	22.0	19	51.4	1	6.7
IV	15	100.0	46	78.0	18	48.6	14	93.3
Immune diagnosis
Desert	7	46.7	19	32.2	8	21.6	2	13.3
Excluded	5	33.3	26	44.1	21	56.8	10	66.7
Inflamed	2	13.3	10	16.9	6	16.2	3	20.0
Dual phenotype	1	6.7	4	6.8	2	5.4	0	0.0

126 samples from different anatomical metastatic sites were collected from 116 patients.